共 50 条
- [21] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN StudyBLOOD, 2023, 142Shah, Nirav N.Zinzani, Pier LuigiWang, Michael L.Nasta, Sunita D.Lech-Maranda, EwaOgawa, YoshiakiFakhri, BitaKuss, BryoneMiyashita, KanamePatel, KrishCoombs, Catherine C.Ma, ShuoPatel, ManishBarve, Minal A.Tessoulin, BenoitStathis, AnastasiosKim, Won SeogEnnishi, DaisukeHashimoto, DaigoKojima, KensukeZelenetz, Andrew D.Cohen, Jonathon B.Vose, Julie M.Maddocks, Kami J.Munir, TalhaSun, FangfangBian, FaithTsai, Donald E.Abada, PaoloCheah, Chan Y.
- [23] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenstrom Macroglobulinemia: Results from the Phase 1/2 BRUIN StudyBLOOD, 2022, 140Palomba, M. LiaPatel, Manish R.Eyre, Toby A.Jurczak, WojciechLewis, David JohnGastinne, ThomasMa, ShuoCohen, Jonathon B.Patel, KrishBrown, Jennifer R.Scarfo, LydiaMunir, TalhaLech-Maranda, EwaHoffmann, MarcUjjani, Chaitra S.Fakhri, BitaWang, Michael L.Izutsu, KojiNagai, HirokazuTam, Constantine S.Seymour, John F.Rhodes, Joanna M.Vose, Julie M.McKinney, MatthewGerson, James N.Barve, Minal A.Kuss, Bryone J.Koh, YoungilGao, WeiRuppert, Amy S.Walgren, Richard A.Tsai, Donald E.Nair, BinojBao, KatherineMato, Anthony R.Cheah, Chan Y.
- [24] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN StudyBLOOD, 2023, 142Patel, KrishVose, Julie M.Nasta, Sunita D.Brown, Jennifer R.Maddocks, Kami J.Woyach, Jennifer A.Shah, Nirav N.Fakhri, BitaTessoulin, BenoitMa, ShuoJagadeesh, DeepaLech-Maranda, EwaCoombs, Catherine C.Patel, ManishRhodes, Joanna M.Ujjani, Chaitra S.Hoffmann, Marc S.Cheah, Chan Y.Munir, TalhaLewis, DavidScarfo, LydiaEyre, Toby A.Alencar, Alvaro J.Cohen, Jonathon B.Zelenetz, Andrew D.Tsai, Donald E.Li, MeiBian, FaithAbada, PaoloZinzani, Pier Luigi
- [25] Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 StudyBLOOD, 2023, 142Song, YuqinYi, ShuhuaYang, HaiyanFeng, RuHuang, HuiqiangZhang, QingyuanLiu, YanyanGuo, YeZhang, HuilaiZhang, LilingQian, YijiaoZhu, JianKunZhu, Jun
- [26] Pirtobrutinib, a Highly Selective, NonCovalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S394 - S395Cohen, Jonathon B.Shah, Nirav N.Alencar, Alvaro J.Gerson, James N.Patel, Manish R.Fakhri, BitaJurczak, WojciechTan, Xuan NiLewis, Katharine L.Fenske, TimothyCoombs, Catherine C.Flinn, Ian W.Lewis, David J.Le Gouill, StevenPalomba, M. LiaWoyach, Jennifer A.Pagel, John M.Lamanna, NicoleBarve, Minal A.Ghia, PaoloEyre, Toby A.Zinzani, Pier LuigiUjjani, Chaitra S.Koh, YoungilIzutsu, KojiLech-Maranda, EwaTam, Constantine S.Sundaram, SuchitraYin, MingNair, BinojTsai, Donald E.Balbas, MinnaMato, Anthony R.Cheah, Chan Y.Wang, Michael L.
- [27] Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naive Cohort in the Phase 1/2 BRUIN StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S350 - S350Wierda, William G.Eyre, Toby A.Lech-Maranda, EwaRoeker, Lindsey E.Patel, ManishFukuhara, NorikoWoyach, Jennifer A.Brown, Jennifer R.Patel, KrishTam, Constantine S.Fahkri, BitaAbada, PaoloTsai, Donald E.Sizelove, RichardJurczak, Wojciech
- [28] Efficacy of Pirtobrutinib in BTK-Inhibitor Pre-treated Relapsed/ Refractory CLL/SLL: Phase 1/2 BRUIN Study Results by Prior BCL2-Inhibitor TherapyONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 119Woyach, Jennifer A.Brown, Jennifer R.Ghia, PaoloRoeker, Lindsey E.Patel, KrishEyre, Toby A.Munir, TalhaLech-Maranda, EwaLamanna, NicoleTam, Constantine S.Seymour, JohnShah, Nirav N.Ujjani, ChaitraFahkri, BitaCoombs, Catherine C.Flinn, IanPatel, Manisha R.Nasta, Sunita D.Cohen, Jonathon B.Alencar, Alvaro J.Cheah, Chan Y.Ma, ShuoRhoades, Joanna M.Jagadeesh, DeepaZinzani, Pier LuigiOsterborg, AndersIzutsu, KojiTsai, Donald E.Abada, PaoloBalbas, MinnaRuppert, Amy S.Li, JianJurczak, WojciechWierda, William G.Stilgenbauer, Stephan
- [29] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN StudyBLOOD, 2022, 140 : 2316 - 2320Mato, Anthony R.Woyach, Jennifer A.Brown, Jennifer R.Ghia, PaoloPatel, KrishEyre, Toby A.Munir, TalhaLech-Maranda, EwaLamanna, NicoleTam, Constantine S.Seymour, John F.Shah, Nirav N.Coombs, Catherine C.Ujjani, Chaitra S.Patel, Manish R.Fakhri, BitaCheah, Chan Y.Alencar, Alvaro J.Cohen, Jonathon B.Gerson, James N.Flinn, Ian W.Ma, ShuoJagadeesh, DeepaRhodes, Joanna M.Hernandez-Ilizaliturri, FranciscoZinzani, Pier LuigiBalbas, MinnaNair, BinojAbada, Paolo B.Wang, ChunxiaoWang, DeniseTsai, Donald E.Wierda, William G.Jurczak, Wojciech
- [30] Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN studyLANCET HAEMATOLOGY, 2024, 11 (09): : e682 - e692Wierda, William G.Shah, Nirav N.Cheah, Chan Y.Lewis, DavidHoffmann, Marc S.Coombs, Catherine C.Lamanna, NicoleMa, ShuoJagadeesh, DeepaMunir, TalhaWang, YucaiEyre, Toby A.Rhodes, Joanna M.McKinney, MatthewLech-Maranda, EwaTam, Constantine S.Jurczak, WojciechIzutsu, KojiAlencar, Alvaro J.Patel, Manish R.Seymour, John F.Woyach, Jennifer A.Thompson, Philip A.Abada, Paolo B.Ho, CalebMcNeely, Samuel C.Marella, NarasimhaNguyen, BastienWang, ChunxiaoRuppert, Amy S.Nair, BinojLiu, HuiTsai, Donald E.Roeker, Lindsey E.Ghia, Paolo